Factors including hospital consolidation and increasing price transparency bring growing pricing pressure to medtech manufacturers. In this context, more manufacturers are considering new approaches to value-based pricing to maximize opportunity while minimizing risk, according to this expert column from Matthew Majewski and Kira Gordon.
ESMO 2025 Review: Bring me the horizon
From these sessions, CRA’s Aaron Everitt highlighted that while there are still relevant data releases and findings on existing immune checkpoint inhibitors,...